At a glance
- Originator Merck & Co
- Class Analgesics; Aromatic amino acids
- Mechanism of Action Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Migraine; Pain; Rheumatoid arthritis
Most Recent Events
- 06 Oct 1998 No-Development-Reported for Migraine in United Kingdom (Unknown route)
- 06 Oct 1998 No-Development-Reported for Migraine in USA (Unknown route)
- 06 Oct 1998 No-Development-Reported for Rheumatoid arthritis in United Kingdom (Unknown route)